Wells Fargo’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-144
| Closed | -$383 | – | 7737 |
|
|
2024
Q1 | $383 | Buy |
144
+3
| +2% | +$7 | ﹤0.01% | 6342 |
|
|
2023
Q4 | $334 | Buy |
141
+7
| +5% | +$12 | ﹤0.01% | 6475 |
|
|
2023
Q3 | $188 | Buy |
134
+13
| +11% | +$31 | ﹤0.01% | 6603 |
|
|
2023
Q2 | $367 | Sell |
121
-4,982
| -98% | -$19.2K | ﹤0.01% | 6549 |
|
|
2023
Q1 | $31.9K | Buy |
5,103
+4,801
| +1,590% | +$29.3K | ﹤0.01% | 5410 |
|
|
2022
Q4 | $1.84K | Buy |
+302
| New | +$2.46K | ﹤0.01% | 6029 |
|
|
2022
Q3 | – | Sell |
-285
| Closed | -$4K | – | 7631 |
|
|
2022
Q2 | $4K | Sell |
285
-926
| -76% | -$8.62K | ﹤0.01% | 6132 |
|
|
2022
Q1 | $14K | Sell |
1,211
-10,715
| -90% | -$118K | ﹤0.01% | 6162 |
|
|
2021
Q4 | $211K | Buy |
11,926
+11,880
| +25,826% | +$251K | ﹤0.01% | 5231 |
|
|
2021
Q3 | $1K | Sell |
46
-93
| -67% | -$2.02K | ﹤0.01% | 6842 |
|
|
2021
Q2 | $3K | Sell |
139
-4,077
| -97% | -$104K | ﹤0.01% | 6490 |
|
|
2021
Q1 | $131K | Buy |
+4,216
| New | +$147K | ﹤0.01% | 5360 |
|
Wells Fargo's KNTE Position: Q2 2024 in Review
Wells Fargo sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 144 shares — an estimated $383 sold.
Wells Fargo first reported a position in KNTE in Q1 2021 and held it in 12 quarters. The position peaked at $211K in Q4 2021. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.
- Wells Fargo reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Wells Fargo sold 144 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $383.
- Wells Fargo first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2021 and held it in 12 quarters.
- Wells Fargo's Kinnate Biopharma Inc. Common Stock position peaked at $211K in Q4 2021.
- 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.
Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.